CELL SURFACE HUMAN B CELL STIMULATORY FACTOR I RECEPTOR
'25 I-labeled BSF-1 and put through the iodination protocol with omission of "'l, Bioactivity of 125 I-BSF-1 was determined in the human B cell proliferation assay described above.
Binding Assays and Data Analysis . Binding assays were performed by a phthalate oil separation method (24) essentially as described previously for murine '25 I-GM-CSF (23) . Sodium azide (0.2%) was included in all binding assays to inhibit internalization and degradation of '25 I-BSF-1 by cells at 37°C . Adherent human gingival fibroblasts were assayed by incubating confluent monolayers in six-well plates (prepared as described above) with 125 1-BSF-1 in 1 ml of RPMI-1640 containing 2% BSA, 20 mM Hepes buffer, and 0.2% sodium azide, pH 7.2 (binding medium) . Plates were incubated on a gyratory shaker for either 1 h at 37'C or 2 h at VC, C, after which an aliquot of the supernatant in each well was removed and counted in a gamma counter, and the monolayers were washed rapidly once with 5 ml of binding medium and three times with 5 ml of PBS . After incubation in 1 ml of trypsin-EDTA at 370 C for 15 min, cells were harvested and the entire aliquot was counted in a gamma counter . The number of cells per well was determined by harvesting and counting cells from control wells that had undergone the same incubation and wash conditions in the absence of 125 1-BSF-1 .
Association and dissociation kinetic experiments were conducted as previously described (23) . Binding data was also analyzed, as described elsewhere (23) .
Affinity Crosslinking. Crosslinking experiments with human 125 1-BSF-1 to Raji cells were performed as previously described for murine BSF-1 (12) . For human gingival fibroblasts, confluent monolayers of cells in 9-cm dishes were incubated with '25I-BSF-1 (1 .3 X 10-9 M) at 4°C in 3 ml of binding medium both in the presence and absence of a 100-fold or greater molar excess of unlabeled BSF-1 . After 2 h the plates were washed three times in ice-cold PBS, and 4 ml of 0.1 mg/ml bis-(sulfosuccinimidyl) suberate (BS3) in PBS was added to each . After a 30-min incubation at 25'C, plates were again washed three times with PBS and cells were harvested by scraping and centrifugation, after a 15-min incubation at 37°C in 4 ml of 5 mM EDTA. Cells were then incubated in 50 Al PBS/I% Triton containing 2 mM phenylmethylsulfonylfluoride, 10 AM pepstatin, 10 AM leupeptin, 2 mM o-phenanthroline, and 2 mM EGTA for 30 min at 25°C, centrifuged at 12,000 g for 10 min, and the supernatants were retained.
SDS-PAGE . Samples were boiled for 3 min in sample buffer (0.06 M Tris-HCI, pH 6.8, 2% SDS, 10% glycerol, 5% 2-ME) and analyzed on 8, 10, or 10-20% gradient gels according to the stacking gel procedure of Laemmli (25) . Methyl [' 4C]-labeled molecular markers : cytochrome C (M,, 12,300), lactoglobulin A (Mr , 18,367), carbonic anhydrase (Mr , 31,000), ovalbumin (M,, 46,000), BSA (M,, 69,000), phosphorylase B (A, 97,400), and myosin (M,, 200,000) were from New England Nuclear (Boston, MA). After electrophoresis, gels were stained with Coomassie blue (0.25% in 25% isopropanol, 10% acetic acid), dried and then exposed to Kodak X-omat AR film at -70'C.
Results
Purification and Radiolabeling of Human BSF-1 . Recombinant human BSF-1 was expressed in yeast, purified to apparent homogeneity as described in Materials and Methods, and iodinated to high specific activity with the enzymobead radioiodination reagent . Fig . 1 , lane a, shows an autoradiograph of an iodinated recombinant human BSF-1 preparation, which exhibits a broad band of^-60,000 Mr (average) . Radiolabeled preparations of BSF-1 were calculated to have specific activities in the range of 2-6 X 10' 5 cpm/mmol, based on protein concentrations determined by amino acid analysis . Such preparations retained >50% of their biological activity (as measured in a human B cell proliferation assay), and were stable for at least 1 mo when stored at 4°C in medium containing 2% BSA and 0.2% sodium azide . Treatment of recombinant human BSF-1 with N-glycanase resulted in the appearance of a major species after iodination (sp act, 2.5 X 10 ' 5 479 FIGURE I . Characterization of human '25 I-BSF-1 by SDS-PAGE.
Lane a, "5 I-labeled recombinant BSF-1, sp act 3.2 X 10'5 cpm/mmole; and (b) '25 I-labeled N-glycanase-treated BSF-I, sp act 2.5 X 10`5 cpm/mmole were boiled in sample buffer containing 2% SDS and 5% 2-ME, and 5,000 cpm were applied to a linear 10-20% gradient gel. Electrophoresis and autoradiography were conducted as described under Materials and Methods.
cpm/mmol) of^-15,000 M,. (Fig. 1, lane b) . The relative molecular mass of the digested protein is similar to the molecular weight of the nonglycosylated protein predicted from its cDNA sequence, and suggests that recombinant human BSF-1 is extensively glycosylated by the yeast host, similar to that previously observed with yeast-derived recombinant murine BSF-1 (12) .
Binding Characteristics of BSF-1 with Cell Surface Receptors . Binding studies undertaken with the glycosylated form of human BSF-1 showed that it exhibited specific binding to the human B cell line, Raji (26) . Preliminary experiments showed that binding was saturable and extremely rapid, requiring <30 min to reach equilibrium at either 37 or 4°C. Fig. 2A illustrates the association kinetics at 37°C of 125 1-BSF-1 with Raji cells, showing that both the final equilibrium amount of ligand bound to cells and the approach to equilibrium are dependent on the initial concentration of 125 1-BSF-1 in the medium. Although the initial rate of binding is so rapid that it makes collection of data at early times difficult, the best-fit single exponential time-dependency curves passing through the data (27) are consistent with the presence of a single population of receptors on these cells. The inset (Fig. 2B) shows a plot of the pseudo-first-order forward rate constants determined from the curves in Fig. 2A relative to the initial concentration of 125 1-BSF-1 in the medium . The data shown fit a straight line, as expected for a biomolecular reaction, and generate values of 3.36 ± 0.43 X 10"/M-min for the forward rate constant (the slope) and 0.22 ± 0.03/min for the reverse rate constant (the intercept on the ordinate). the fast component were 7 .6 ± 0 .9 X 10-2/min in medium alone and 6 .1 ± 0.8 X 10 -'/min in the presence of excess unlabeled BSF-1, while in both cases the rate constant of the slow component was <I 0-2/min. Comparison of these rates revealed no significant sensitivity to receptor occupancy, suggesting that BSF-1 receptors on Raji cells are noncooperative (28) . Using the average value for the fast component of 6 .9 ± 1 .6 X 10-2/min, a ratio of the forward and reverse rate constants gives a range of values for the affinity constant of radiolabeled BSF-1 for its receptor of 2.6-7 .2 X 109/M . This range is likely to be somewhat low, both because it does not take into account the slow component of the dissociation kinetics and because the difficulties in accurately measuring the extremely rapid initial rate of 1251-BSF-1 binding may in fact underestimate the forward rate constant. This latter problem may also contribute to the somewhat higher value for the reverse rate constant determined from the association kinetics experiments. Fig. 3 illustrates typical equilibrium binding data for 125 1-BSF-1 to Raji cells at 37'C (Fig.3 A) , as well as to adherent human gingival fibroblasts at 4°C (Fig.  3B) . Scatchard analysis of the data yielded a straight line, indicative of a single class of binding sites for BSF-1 on both cell types. Nonspecific binding was extremely low (<0 .1% of the total cpm added) and increased linearly with increasing concentration . From the average of eight binding experiments, the calculated apparent Ka of BSF-1 binding to Raji cells was 6.10 ± 2.15 X 10 9/M with 2,160 ± 530 specific binding sites per cell . This Ka was in the same range as that obtained by analysis of association and dissociation kinetics (4.9 ± 2.3 X 10 9/M). Similar experiments carried out at 4°C showed an apparent Ka of 6.12 ± 1 .12 X 10 9/M with 1,670 ± 300 specific sites per cell, values that are not significantly different than those obtained at 37°C. Binding of BSF-1 to human gingival fibroblasts also yielded similar values, with a calculated Ka of 1 .1 ± 0.1 X 10'0/M and 1,950 ± 70 specific sites per cell . In addition, inhibition experiments with nonglycosylated human BSF-1 (Nglycanase treated) yielded an inhibition constant indistinguishable from that of the glycosylated form (data not shown) . Equilibrium binding experiments also showed the iodinated nonglycosylated BSF-1 to have a similar Ka (3.50 ± 0.55 X 10 9/M) to that of the glycosylated form. Consequently, this nonglycosylated material was judged to be a suitable analogue to glycosylated BSF-1 for affinity crosslinking experiments, in which its smaller, more homogeneous size is a distinct advantage (see below) .
The specificity of human BSF-1 binding to Raji cells was assessed by testing a number of purified lymphokines and other polypeptide hormones for their ability to compete with ' 251-BSF-1 binding to its receptor (Fig. 5 ). When present in concentrations that were 100-1,000-fold greater (on a molar basis) than that of 125 1-BSF-1, human BSF-1 eliminated >95% of 1251-BSF-1 binding, while none of the other molecules tested, including human IL-1, IL-2, GM-CSF, and G-CSF, exhibited any ability to compete.
Cellular Distribution ofHuman BSF-1 Receptors . Cell lines of human, monkey, and mouse origin were examined for their ability to bind human '251-BSF-1 (Table I) . In all cases, complete binding curves were done over a range of '25I-BSF-1 concentrations, and receptor numbers per cell were generated by Scatchard analysis of the data . Reminiscent of the broad cellular distribution of murine BSF-1 receptors, human BSF-1 was found to bind to cells of all human lineages examined, including fibroblasts and epithelial cells. Human BSF-1 also bound to both monkey lines tested, but not to any murine lines. Although receptor levels varied over a 25-fold range, expression on most cells was extremely low. Two human T lymphoma lines, RPMI-8402 and JMB12, did not exhibit detectable levels of BSF-1 receptor. Peripheral blood mononuclear cells also express low receptor levels when resting, but appear to increase their receptor numbers by about fivefold upon stimulation with PHA.
Affinity Crosslinking. Further characterization of the BSF-1 receptor on Raji cells and human gingival fibroblasts, both of which express^-2,000 receptors/cell, was carried out by affinity crosslinking. Radiolabeled nonglycosylated BSF-I (Nglycanase treated) was bound to cells in the presence or absence of unlabeled BSF-I and cells subsequently exposed to the bifunctional crosslinking reagent BS', extracted with PBS/ I% Triton containing a cocktail of protease inhibitors, and the soluble fractions were analyzed by SDS-PAGE . Fig. 6 shows a SDS-PAGE analysis, run under reducing conditions, of "5I-BSF-I crosslinked to Raji cells and human gingival fibroblasts. One major crosslinked band was observed on both cell types (Fig. 6, lanes b and d) . Controls showed that no crosslinked species were found in the absence of crosslinker (lane a) or in a sample containing excess unlabeled BSF-I (Fig. 6, lane c) . From crosslinking experiments run on both 8 min in sample buffer containing 2% SDS and 5% 2-ME, and subjected to electrophoresis on a 10% gel.
and 10% polyacrylamide gels, an average relative molecular mass for the crosslinked species on both Raji cells and gingival fibroblasts was calculated to be 154,000 ± 5,000. After subtraction of BSF-1 (15,000 M,), the crosslinked species would be a membrane protein of Mr 139,000 ± 5,000. Discussion 125 I-labeled recombinant human BSF-1 was used to examine the cellular distribution of receptors for this lymphokine, as well as to further characterize these receptors on both Raji cells, a human B lymphoma, and on primary human gingival fibroblasts. Reminiscent of the broad cellular distribution previously shown for BSF-1 receptors on murine cells (12, 13) , BSF-1 receptors were found on in vitro human cell lines of B, T, and hematopoietic lineages . This distribution has now been further extended by the detection of BSF-1 receptors on a number of adherent human cell lines of both epithelial and endothelial character, as well as on primary gingival fibroblasts. Using ' 21 I-labeled murine BSF-l, we have also observed BSF-1 receptors on similar murine cell lines (L. Park, unpublished data) . The low level of expression of BSF-1 receptors on human cells was comparable to that seen on mouse cells, and stimulation of human peripheral blood mononuclear cells with PHA resulted in an approximate fivefold increase in BSF-1 receptor expression, similiar to the increased expression of BSF-1 receptors reported after activation of primary murine B and T cells (12, 13) .
Comparison of the binding characteristics of the yeast hyperglycosylated form of BSF-1 (M,. 60,000) and the N-glycanase-treated, sugar-free form on Raji cells showed no significant differences in kinetic parameters . This provides evidence that the addition of carbohydrate to the BSF-1 molecule at natural glycosylation sites does not alter the binding characteristics of human BSF-1 for its receptor. This result is in agreement with results with murine BSF-1, where very similar binding characteristics were obtained by us (12) using a recombinant yeast-derived hyperglycosylated species (M, 49,000), and by Ohara and Paul (13) using natural BSF-1 (A 20,000).
Equilibrium binding of human BSF-1 to Raji cells and gingival fibroblasts revealed no obvious differences between the receptors found on these cells. Similarly, preliminary structural information on the BSF-I receptor obtained by affinity crosslinking showed that both Raji cells and gingival fibroblasts exhibited a crosslinked species having an average M, of 154,000, which would correspond to a receptor subunit size of 139,000 Mr. The large size of the crosslinked species was unexpected from our previous crosslinking data, which showed a receptor size of^-75,000 M, on a number of murine cell lines (12) , and from similar experiments by Ohara and Paul which showed a receptor size on murine spleen cells of 60,000 M, (13) . Several explanations for this discrepancy can be suggested : (a) the BSF-1 receptor on human and mouse cells may differ by 60,000-80,000 M,-. While human and murine BSF-1 exhibit considerable amino acid sequence homology (14) , they show complete species specificity in receptor binding, suggesting that substantial differences might exist in receptor structure between the two species. (b) A large difference in apparent receptor size could be caused by species-specific differences in the posttranslational modification of a similar protein core. (c) The BSF-1 receptor may be composed ofa complex of two or more proteins, and human BSF-1 may crosslink to a different component of the complex than murine BSF-I . (d ) Finally, the receptor size we observed on murine cells may represent a proteolytically cleaved fragment of the native receptor. In previous work with the murine GM-CSF receptor (23), we showed that this receptor was acutely protease sensitive, and if extracted from cells in the absence of a cocktail of protease inhibitors, it would be degraded from a 130,000 to a 70,000 M, form. Depending on the cell type involved, some degradation could not be prevented even in the presence of the protease inhibitor cocktail . We have used the same protease inhibitor cocktail for extractions during crosslinking studies with both mouse and human BSF-1, however the murine receptor may be more protease sensitive than the human receptor . We are currently investigating the possibility that the native receptor on murine cells is actually comparable in size to that on Raji cells and human gingival fibroblasts.
Although the diversity of biological activities attributable to BSF-1 is substantial, they have thus far been limited to effects on cells of lymphoid or myeloid origin . With the observation that BSF-1 is also capable of binding to fibroblasts, this lymphokine may soon join the ranks of other regulatory molecules such as interleukin 1 (30) and transforming growth factor /3 (31), the receptors for which are expressed on a wide array of different tissues and which appear to be involved in a complex network of biological activities. Molecules such as interleukin 1, 0 interferon, transforming growth factor a, and tumor necrosis factor are known to stimulate fibroblast growth (32, 33) and secretion of prostaglandins, collagenase, and collagen (34) (35) (36) , and have recently been implicated in regulating the release of cytokines from fibroblasts as well (37) . Future studies on BSF-1 and its receptor should clarify the role that this molecule may play in a complex regulatory system of cytokines that bridge hematopoietic, connective tissue, and lymphoid compartments . Summary ' 25 I-labeled recombinant human B cell stimulatory factor 1 (BSF-1) was used to characterize receptors specific for this lymphokine on in vitro cell lines representing human B, T, and hematopoietic lineages, as well as on adherent cell lines of epithelial and endothelial origin, and on primary human gingival fibroblasts. BSF-1 binding was extremely rapid and saturable at both 4 and 37°C, with a slow dissociation rate . On all human cell types examined, BSF-1 bound to a single class of high-affinity receptor (<3,000 receptors per cell) with a Ka of 0.5-1 .0 X 10 1°/M. Human BSF-1 also bound to cell lines of simian but not murine origin . Comparison of kinetic characteristics obtained with a yeastderived hyperglycosylated form of BSF-1 (M, 60,000) and N-glycanase-treated, sugar-free BSF-1 (Mr 15,000) showed no significant differences. Among a panel of lymphokines and growth hormones, only unlabeled human BSF-1 was able to compete for the binding of 115I-labeled human BSF-1 . Affinity crosslinking experiments resulted in the identification on both Raji cells and on primary human gingival fibroblasts of a receptor subunit with an average Mr of 139,000. These studies show that the BSF-1 receptor on human cells has an extremely broad cellular distribution, while further supporting the notion that the ability of BSF-1 to mediate a spectrum of biological activities cannot be accounted for by overt differences in the receptor for this lymphokine on different cell lineages .
